CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies that ...
A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC). This is an ASCO Meeting Abstract from the 2015 ASCO Annual ...
While early stage and involving a relatively small patient population, the interim phase Ib readout from the combination cohort testing estrogen receptor (ER)-targeting candidate vepdegestrant in ...
Minneapolis-based Celcuity Inc. sealed a deal for the rights to Pfizer Inc.’s pan-PI3K/mTOR inhibitor, gedatolisib, for ER-positive/HER2-negative advanced or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results